3.08
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Is Vistagen Therapeutics Inc. stock a good hedge against inflationAI Powered Stock Call - Metal.it
Vistagen Therapeutics Inc. Stock Analysis and ForecastSky-high return potential - PrintWeekIndia
Does Vistagen Therapeutics Inc. stock pay reliable dividendsBreakneck growth rates - jammulinksnews.com
Vistagen Showcases Revolutionary Nose-to-Brain Drug Platform: CEO Fireside Chat at BTIG Conference - Stock Titan
What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional
Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com
What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
What makes Vistagen Therapeutics Inc. stock price move sharply2x Return Forecast - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat
How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan
Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Developm - GuruFocus
Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - MSN
William Blair Issues Negative Forecast for VTGN Earnings - Defense World
William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat
Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
자본화:
|
볼륨(24시간):